CARB-X 2021-22 ANNUAL REPORT LAUNCHED

CARB-X published its 2021-2022 annual report today. The report highlights achievements, including CARB-X projects in clinical development, new products on the market, renewed funding commitments, open funding rounds, and Portfolio Acceleration Tools, a series of research projects led by CARB-X to support multiple product developers.

Over the past year, CARB-X product developers made tremendous progress advancing their projects through the development pipeline:

• 8 prevention and therapeutic candidates began or progressed through Phase 1 and Phase 1b clinical trials. These represent a range of modalities, including broad-spectrum antibiotics by Bugworks and Peptilogics, biofilm-targeting monoclonal antibodies by Trellis Bioscience and Clarametyx Biosciences, a CRISPR-engineered bacteriophage by SNIPR Biome, a live biotherapeutic candidate by Seres Therapeutics, and both a vaccine and a small-molecule anti-virulence inhibitor by GlaxoSmithKline;
• Vedanta Biosciences entered Phase 3 clinical trials with a live biotherapeutic candidate;
• 2 diagnostics by HelixBind and Proteus entered the verification and validation stage; and
• 2 diagnostics by T2 Biosystems and Specific Diagnostics (acquired by bioMérieux in 2022) are now on the market.